A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion SR and Placebo in Subjects With Obesity Participating in a Behavior Modification Program

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion SR and Placebo in Subjects With Obesity Participating in a Behavior Modification Program

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Naltrexone/bupropion (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms COR-BMOD
  • Sponsors Orexigen Therapeutics
  • Most Recent Events

    • 26 Mar 2018 Based on the data from COR-I, COR-II, COR-BMOD, and COR-Diabetes trials, the Health Canada has approved CONTRAVE extended-release tablets for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults, as reported in a Valeant Canada media release.
    • 10 Jun 2017 Biomarkers information updated
    • 25 Apr 2017 According to an Orexigen Therapeutics media release, Health Canada has completed its screening phase and accepted for review a New Drug Submission for marketing approval of Contrave (naltrexone HCl and bupropion HCl). The regulatory submission was filed by Valeant Canada, an affiliate of Valeant Pharmaceuticals International, Inc.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top